A quadral biosignature of IFN-γ, IL-2, IL-12 and IP-10 increases the diagnostic potential for latent tuberculosis among diabetic patients in Uganda

Diabetes mellitus impairs Th1, inflammatory, and regulatory cytokine and chemokine responses during LTBI. A multivariate biosignature of IFN-γ, IL-2, IL-12 and IP-10 outperforms single-marker assays (e.g., variability in IFN-γ due to immunosuppression in DM) and offers robust identification of LTBI regardless of DM status, highlighting the additive value of combining mediators that capture distinct immunological axes. The improved biosignature specificity may minimise false positives in DM populations, who often exhibit comorbidities that could mimic LTBI-associated inflammation. Our findings support validating combined biomarker approaches to enhance LTBI diagnosis and prognosis in the immunocompromised DM population.

Authors

Institutions

Publication Details

Journal
BMC Immunology
Published
2025-11-07
DOI
https://doi.org/10.1186/s12865-025-00771-y
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A quadral biosignature of IFN-γ, IL-2, IL-12 and IP-10 increases the diagnostic potential for latent tuberculosis among diabetic patients in Uganda

Andrew Peter Kyazze, Bernard S. Bagaya, Reinout van Crevel, Davis Kibirige et al.
BMC Immunology
Tuberculosis Research and Epidemiology
article

A quadral biosignature of IFN-γ, IL-2, IL-12 and IP-10 increases the diagnostic potential for latent tuberculosis among diabetic patients in Uganda

Andrew Peter Kyazze, Bernard S. Bagaya, Reinout van Crevel, Davis Kibirige, Stephen Cose, Obondo James Sande, Phillip Ssekamatte, Irene Andia Biraro, Marjorie Nakibuule, Rose Nabatanzi, Diana Sitenda, David Patrick Kateete
article en

Abstract

Diabetes mellitus impairs Th1, inflammatory, and regulatory cytokine and chemokine responses during LTBI. A multivariate biosignature of IFN-γ, IL-2, IL-12 and IP-10 outperforms single-marker assays (e.g., variability in IFN-γ due to immunosuppression in DM) and offers robust identification of LTBI regardless of DM status, highlighting the additive value of combining mediators that capture distinct immunological axes. The improved biosignature specificity may minimise false positives in DM populations, who often exhibit comorbidities that could mimic LTBI-associated inflammation. Our findings support validating combined biomarker approaches to enhance LTBI diagnosis and prognosis in the immunocompromised DM population.

BMC ImmunologyVol. 26(1)
Radboud University Nijmegen (NL), Rubaga Hospital (UG), Radboud University Medical Center (NL), Makerere University (UG), Uganda Virus Research Institute (UG)
European Commission, European and Developing Countries Clinical Trials Partnership
Openalex Percentile: Top 61%
Tuberculosis Research and Epidemiology
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.